ClinicalTrials.gg
CompletedNCT04451772Updated Jan 14, 2025Results posted

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

A Phase 2 interventional study of Elsubrutinib and Placebo for Elsubrutinib in Systemic Lupus Erythematosus (SLE), sponsored by AbbVie. Completed at 87 sites in 18 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-14.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
121st of 407
185 · median 70
Started
2020
with 14 others
Phase 2
120 of 477
10 open now
Registered
311th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 121st largest by enrollment of the 407 interventional ones that give a count, is one of 15 that started in 2020, is one of 120 in phase 2, and was the 311th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will evaluate how well elsubrutinib and upadacitinib given alone or as the ABBV-599 combination (elsubrutinib/upadacitinib) works within the body, in participants who completed study M19-130. This study will assess the change in disease symptoms.

ABBV-599 is an investigational drug being developed for the treatment of Systemic Lupus Erythematosus (SLE). This study is "double-blinded", which means that neither the trial participants nor the study doctors will know who will be given which study drug. Study doctors put the participants into 1 of 4 groups called treatment arms. Each group receives a different treatment. Adult participants with a diagnosis of SLE will be enrolled. Around 260 participants will be enrolled in the study in approximately 100 sites worldwide.

Participants will receive the following for up to 56 weeks:

Participants will receive oral elsubrutinib capsules and/or oral upadacitinib tablets once daily for up to 56 weeks. Participants who were receiving elsubrutinib and/or upadacitnib in M19-130 will continue to receive the same treatment in this study. Participants who were receiving placebo in M19-130 will be re-randomized to one of the 2 combination treatment arms in this study.

Arm 1: Elsubrutinib Dose A and Upadacitinib Dose A Arm 2: Elsubrutinib Dose A and Upadacitinib Dose B

There may be higher burden for participants in this trial compared to their standard of care. Participants will attend monthly visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Systemic Lupus Erythematosus (SLE)

Keywords

  • Systemic Lupus Erythematosus
  • ABBV-599
  • ABBV-105
  • ABT-494
  • Elsubrutinib
  • Upadacitinib
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed Study M19-130 (i.e., the randomized controlled trial of elsubrutinib, upadacitinib, and ABBV-599 [elsubrutinib/upadacitinib] combination or matching placebo) and will not have developed any laboratory or clinical discontinuation criteria as defined in that study.
  • On stable background treatment for SLE throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Active, chronic, or recurrent viral, or bacterial infection.
  • Active tuberculosis (TB)
  • History of gastrointestinal (GI) perforation, diverticulitis, or a significantly increased risk for GI perforation per investigator assessment.
  • Participant require vaccination with during study participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
185 participants (actual)

Study arms

  • Experimental
    ABBV-599 High Dose (Elsubrutinib 60 mg/upadacitinib 30 mg) -> ABBV-599 High Dose

    Participants received elsubrutinib 60 mg capsules once a day by mouth and upadacitinib 30 mg film-coated tablets once a day by mouth for 48 weeks in Study M19-130. Participants continued on this regimen in the current study (M20-186) for up to 56 weeks.

    Drug: Elsubrutinib · Drug: Upadacitinib

  • Experimental
    Elsubrutinib placebo/upadacitinib 30 mg -> Elsubrutinib placebo/upadacitinib 30 mg

    Participants received placebo capsules for elsubrutinib once a day by mouth and upadacitinib 30 mg film-coated tablets once a day by mouth for 48 weeks in Study M19-130. Participants continued on this regimen in the current study (M20-186) for up to 56 weeks.

    Drug: Placebo for Elsubrutinib · Drug: Upadacitinib

  • Experimental
    Elsubrutinib placebo/upadacitinib placebo -> ABBV-599 High Dose

    Participants received placebo capsules for elsubrutinib once a day by mouth and placebo film-coated tablets for upadacitinib once a day by mouth for 48 weeks in Study M19-130. Participants received elsubrutinib 60 mg capsules once a day by mouth and upadacitinib 30 mg film-coated tablets once a day in the current study (M20-186) for up to 56 weeks.

    Drug: Elsubrutinib · Drug: Upadacitinib

  • Experimental
    ABBV-599 Low Dose (Elsubrutinib 60 mg/upadacitinib 15 mg) -> ABBV-599 Low Dose

    Participants received elsubrutinib 60 mg capsules once a day by mouth and upadacitinib 15 mg film-coated tablets once a day by mouth for 48 weeks in Study M19-130. Participants continued on this regimen in the current study (M20-186) for up to 56 weeks.

    Drug: Elsubrutinib · Drug: Upadacitinib

  • Experimental
    Elsubrutinib 60 mg/upadacitinib placebo -> Elsubrutinib 60 mg/upadacitinib placebo

    Participants received elsubrutinib 60 mg capsules once a day by mouth and placebo film-coated tablets for upadacitinib once a day by mouth for 48 weeks in Study M19-130. Participants continued on this regimen in the current study (M20-186) for up to 56 weeks.

    Drug: Elsubrutinib · Drug: Placebo for Upadacitinib

  • Experimental
    Elsubrutinib placebo/upadacitinib placebo -> ABBV-599 Low Dose

    Participants received placebo capsules for elsubrutinib once a day by mouth and placebo film-coated tablets for upadacitinib once a day by mouth for 48 weeks in Study M19-130. Participants received elsubrutinib 60 mg capsules once a day by mouth and upadacitinib 15 mg film-coated tablets once a day by mouth for 48 weeks in the current study (M20-186) for up to 56 weeks.

    Drug: Elsubrutinib · Drug: Upadacitinib

Interventions

  • Capsule; Oral

    Also known as: ABBV-105

  • DrugPlacebo for Elsubrutinib

    Capsule; Oral

  • Film-coated tablet; Oral

    Also known as: ABT-494, RINVOQ

  • DrugPlacebo for Upadacitinib

    Film-coated tablet; Oral

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs) are defined as an adverse event with an onset date that is on or after the first dose of study drug from Study M20-186, and no more than 30 days after the last dose of study drug from Study M20-186. For more details on adverse events please see the Adverse Event section.

    Time frame: From the first dose of study drug in Study M20-186 up to 30 days after the last dose of study drug, up to 442 days

Secondary outcomes

  1. Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI)-4

    SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline in Study M19-130: * ≥4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\]) * No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.

    Time frame: Baseline of Study M19-130 (Week 0), Weeks 56, 64, 72, 80, 88, 96, 104

  2. Percentage of Participants Achieving British Isles Lupus Assessment Group (BILAG)-Based Combined Lupus Assessment (BICLA) Response

    BICLA is a composite responder index. Achievement of BICLA response is defined as improvement in all initial A and B BILAG scores, with no more than one new BILAG B score without worsening of the overall condition (no worsening in Physician's Global Assessment \[PhGA\], \< 0.3 point increase) and no worsening of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.

    Time frame: Baseline of Study M19-130 (Week 0), Weeks 56, 64, 72, 80, 88, 96, 104

  3. Change From Baseline in Daily Prednisone Dose Over Time

    Participants'current use of steroid therapy was assessed at each study visit, and the amount of daily prednisone was documented.

    Time frame: Baseline of M19-130 (Week 0), Weeks 56, 64, 72, 80, 88, 96, 104

  4. Number of Flares Per Patient-year by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLE Disease Activity Index (SLEDAI) Flare Index Through Week 104

    The SELENA SLEDAI flare index defines mild/moderate or severe SLE flares using the SLEDAI score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity.

    Time frame: From Week 56 through Week 104

07

Results

Posted Jan 14, 2025

Participant flow

Participant flow — Overall Study
MilestoneABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High DoseElsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mgElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High DoseABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low DoseElsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib PlaceboElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose
Started454735192514
Completed413831611
Not completed494132413
Withdrew: Adverse event101103
Withdrew: Withdrawal by subject272110
Withdrew: Other, not specified121001
Withdrew: Sponsor decision based on interim analysis data review00011239

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent events (TEAEs) are defined as an adverse event with an onset date that is on or after the first dose of study drug from Study M20-186, and no more than 30 days after the last dose of study drug from Study M20-186. For more details on adverse events please see the Adverse Event section.

Time frame:
From the first dose of study drug in Study M20-186 up to 30 days after the last dose of study drug, up to 442 days
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events
participantsABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High DoseElsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mgElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High DoseABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low DoseElsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib PlaceboElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose
Any TEAE34313011117
TESAE551212
SecondaryPercentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI)-4

SLE Responder Index (SRI)-4 is defined as follows with all criteria compared to Baseline in Study M19-130: * ≥4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score * No worsening of the overall condition (\< 0.3 point increase in Physician's Global Assessment \[PhGA\]) * No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores (i.e., no organ system changes from baseline B/C/D/E to A and no more than 1 organ system changes from baseline C/D/E to B). A letter score is assigned to each organ system with following indications: A = severe, B = moderate, C = mild, D = inactive with prior history, and E = inactive with no history.

Time frame:
Baseline of Study M19-130 (Week 0), Weeks 56, 64, 72, 80, 88, 96, 104
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI)-4
percentage of participantsABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High DoseElsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mgElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose
Week 5671.1 (57.9 to 84.4)76.1 (63.8 to 88.4)54.3 (37.8 to 70.8)
Week 6470.5 (57.0 to 83.9)75.6 (63.0 to 88.1)58.8 (42.3 to 75.4)
Week 7280.5 (68.4 to 92.6)88.9 (79.7 to 98.1)64.7 (48.6 to 80.8)
Week 8075.0 (61.6 to 88.4)82.2 (71.1 to 93.4)57.6 (40.7 to 74.4)
Week 8882.5 (70.7 to 94.3)85.7 (75.1 to 96.3)48.5 (31.4 to 65.5)
Week 9682.9 (71.4 to 94.4)76.9 (63.7 to 90.1)62.5 (45.7 to 79.3)
Week 10485.4 (74.5 to 96.2)82.1 (70.0 to 94.1)61.3 (44.1 to 78.4)
SecondaryPercentage of Participants Achieving British Isles Lupus Assessment Group (BILAG)-Based Combined Lupus Assessment (BICLA) Response

BICLA is a composite responder index. Achievement of BICLA response is defined as improvement in all initial A and B BILAG scores, with no more than one new BILAG B score without worsening of the overall condition (no worsening in Physician's Global Assessment \[PhGA\], \< 0.3 point increase) and no worsening of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score.

Time frame:
Baseline of Study M19-130 (Week 0), Weeks 56, 64, 72, 80, 88, 96, 104
Reported as:
Number · percentage of participants
Percentage of Participants Achieving British Isles Lupus Assessment Group (BILAG)-Based Combined Lupus Assessment (BICLA) Response
percentage of participantsABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High DoseElsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mgElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose
Week 5673.3 (60.4 to 86.3)67.4 (53.8 to 80.9)60.0 (43.8 to 76.2)
Week 6475.0 (62.2 to 87.8)84.4 (73.9 to 95.0)55.9 (39.2 to 72.6)
Week 7273.2 (59.6 to 86.7)88.9 (79.7 to 98.1)61.8 (45.4 to 78.1)
Week 8070.0 (55.8 to 84.2)77.8 (65.6 to 89.9)57.6 (40.7 to 74.4)
Week 8880.0 (67.6 to 92.4)85.7 (75.1 to 96.3)57.6 (40.7 to 74.4)
Week 9678.0 (65.4 to 90.7)76.9 (63.7 to 90.1)59.4 (42.4 to 76.4)
Week 10478.0 (65.4 to 90.7)69.2 (54.7 to 83.7)54.8 (37.3 to 72.4)
SecondaryChange From Baseline in Daily Prednisone Dose Over Time

Participants'current use of steroid therapy was assessed at each study visit, and the amount of daily prednisone was documented.

Time frame:
Baseline of M19-130 (Week 0), Weeks 56, 64, 72, 80, 88, 96, 104
Reported as:
Mean · mg
Change From Baseline in Daily Prednisone Dose Over Time
mgABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High DoseElsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mgElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose
Week 56-3.9 ± 5.96-3.5 ± 5.99-4.9 ± 6.99
Week 64-4.2 ± 5.51-3.7 ± 5.97-5.0 ± 6.87
Week 72-4.0 ± 6.59-4.9 ± 7.23-5.2 ± 6.88
Week 80-5.1 ± 5.96-4.4 ± 8.05-5.2 ± 6.88
Week 88-5.5 ± 5.83-5.2 ± 6.02-6.2 ± 7.04
Week 96-5.5 ± 5.88-5.7 ± 5.78-7.3 ± 6.54
Week 104-5.8 ± 6.02-5.5 ± 5.65-7.7 ± 6.64
SecondaryNumber of Flares Per Patient-year by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLE Disease Activity Index (SLEDAI) Flare Index Through Week 104

The SELENA SLEDAI flare index defines mild/moderate or severe SLE flares using the SLEDAI score, definitions of worsening signs and symptoms, treatment changes, and Physician's Global Assessment of Disease Activity.

Time frame:
From Week 56 through Week 104
Reported as:
Number · Events per patient-year
Number of Flares Per Patient-year by Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) SLE Disease Activity Index (SLEDAI) Flare Index Through Week 104
Events per patient-yearABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High DoseElsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mgElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose
Mild/Moderate0.62 (0.39 to 0.84)1.41 (1.06 to 1.75)1.39 (0.99 to 1.78)
Severe0.00 (0.00 to 0.00)0.04 (-0.02 to 0.10)0.17 (0.03 to 0.31)
Overall0.62 (0.39 to 0.84)1.45 (1.10 to 1.80)1.56 (1.14 to 1.97)

Adverse events

Collected over All-cause mortality and adverse events were collected from the time informed consent was signed through the end of the study. Median time on follow-up was for 422 days for the ABBV-599 High -> ABBV-599 High group; 423 days for the Upa -> Upa and Pbo -> ABBV-599 High groups; 245 days for the ABBV-599 Low -> ABBV-599 Low group; 163 days for the Els -> Els group; and 142.5 days for the Pbo -> ABBV-599 Low group.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High Dose0/45 (0%)5/45 (11.1%)24/45 (53.3%)
Elsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mg0/47 (0%)5/47 (10.6%)18/47 (38.3%)
Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High Dose0/35 (0%)1/35 (2.9%)30/35 (85.7%)
ABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low Dose0/19 (0%)2/19 (10.5%)11/19 (57.9%)
Elsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib Placebo0/25 (0%)1/25 (4%)4/25 (16%)
Elsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose0/14 (0%)2/14 (14.3%)6/14 (42.9%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High DoseElsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mgElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High DoseABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low DoseElsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib PlaceboElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose
SYSTEMIC LUPUS ERYTHEMATOSUSMusculoskeletal and connective tissue disorders0/450/470/350/190/251/14
UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/450/470/350/190/251/14
SKULL FRACTURED BASEInjury, poisoning and procedural complications0/450/470/351/190/250/14
SUBDURAL HAEMATOMAInjury, poisoning and procedural complications0/450/470/351/190/250/14
TRAUMATIC INTRACRANIAL HAEMORRHAGEInjury, poisoning and procedural complications0/450/470/351/190/250/14
HYPOGLYCAEMIAMetabolism and nutrition disorders0/450/470/351/190/250/14
CEREBRAL HAEMATOMANervous system disorders0/450/470/351/190/250/14
NERVOUS SYSTEM DISORDERNervous system disorders0/450/470/351/190/250/14
GASTROENTERITISInfections and infestations0/450/470/350/191/250/14
LUMBAR RADICULOPATHYNervous system disorders0/450/471/350/190/250/14
Most frequent other events
Showing 10 of 79
Most frequent other events
EventABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High DoseElsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mgElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High DoseABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low DoseElsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib PlaceboElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low Dose
COVID-19Infections and infestations8/4511/477/350/191/250/14
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations4/453/476/350/191/250/14
URINARY TRACT INFECTIONInfections and infestations7/453/476/353/191/251/14
HYPOKALAEMIAMetabolism and nutrition disorders0/450/470/352/190/250/14
HYPERTENSIONVascular disorders1/451/470/352/190/251/14
PRURITUSSkin and subcutaneous tissue disorders4/450/470/350/190/250/14
MIGRAINENervous system disorders0/450/473/350/190/250/14
ANAEMIABlood and lymphatic system disorders1/450/470/350/190/251/14
DRY EYEEye disorders0/450/470/350/190/251/14
GASTRITISGastrointestinal disorders1/450/471/350/190/251/14

Baseline characteristics

Full Analysis Set (FAS): all participants who received at least 1 dose of study drug in Study M20-186. Participants are grouped according to treatment sequence as randomized for Studies M19-130 and M20-186. Per protocol, demographic and baseline characteristics are summarized as measured at the start of Study M19-130.

Age, Continuous
Age, Continuous(years)ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High DoseElsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mgElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High DoseABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low DoseElsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib PlaceboElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low DoseTotal
Mean42.8 ± 11.3942.5 ± 12.0040.6 ± 11.7538.3 ± 10.5241.2 ± 11.6042.5 ± 11.5741.6 ± 11.50
Sex: Female, Male
Sex: Female, Male(Participants)ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High DoseElsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mgElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High DoseABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low DoseElsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib PlaceboElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low DoseTotal
Female424235182414175
Male35011010
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ABBV-599 High Dose (Elsubrutinib 60 mg/Upadacitinib 30 mg) -> ABBV-599 High DoseElsubrutinib Placebo/Upadacitinib 30 mg -> Elsubrutinib Placebo/Upadacitinib 30 mgElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 High DoseABBV-599 Low Dose (Elsubrutinib 60 mg/Upadacitinib 15 mg) -> ABBV-599 Low DoseElsubrutinib 60 mg/Upadacitinib Placebo -> Elsubrutinib 60 mg/Upadacitinib PlaceboElsubrutinib Placebo/Upadacitinib Placebo -> ABBV-599 Low DoseTotal
American Indian or Alaska Native3021208
Asian6101263239
Native Hawaiian or Other Pacific Islander0000000
Black or African American26011111
White322620101610114
More than one race25113113
Unknown or Not Reported0000000
08

Study locations

87 sites
  • Duplicate_AZ Arthritis and Rheumotology Research, PLLC /ID# 227833
    Phoenix, Arizona 85032-9306, United States
  • Wallace Rheumatic Studies Center, LLC /ID# 224374
    Beverly Hills, California 90211, United States
  • Valerius Medical Group & Research Center /ID# 223922
    Los Alamitos, California 90720-5402, United States
  • East Bay Rheumatology Medical /ID# 225493
    San Leandro, California 94578, United States
  • University of Colorado Hospital /ID# 245087
    Aurora, Colorado 80045, United States
  • Duplicate_Arthritis & Rheumatic Disease Specialties /ID# 227828
    Aventura, Florida 33180, United States
  • Millennium Research /ID# 233192
    Ormond Beach, Florida 32174, United States
  • IRIS Research and Development, LLC /ID# 227814
    Plantation, Florida 33324, United States
  • Deerbrook Medical Associates /ID# 227330
    Libertyville, Illinois 60048, United States
  • Qualmedica Research, LLC /ID# 227817
    Evansville, Indiana 47714-0805, United States
  • The Center for Rheumatology and Bone Research /ID# 225479
    Wheaton, Maryland 20902, United States
  • Beth Israel Deaconess Medical Center /ID# 222505
    Boston, Massachusetts 02215-5400, United States
  • June DO, PC /ID# 221841
    Lansing, Michigan 48911, United States
  • Duplicate_NYU Langone Health/NYU School of Medicine /ID# 245088
    New York, New York 10016-2772, United States
  • STAT Research, Inc. /ID# 221840
    Vandalia, Ohio 45377-9464, United States
  • Allegheny Health Network Research Institute /ID# 245086
    Pittsburgh, Pennsylvania 15224, United States
  • Dr. Ramesh Gupta /ID# 225524
    Memphis, Tennessee 38119, United States
  • Tekton Research, Inc. /ID# 224411
    Austin, Texas 78745, United States
  • Accurate Clinical Management /ID# 225509
    Houston, Texas 77084, United States
  • SW Rheumatology Res. LLC /ID# 225485
    Mesquite, Texas 75150, United States
  • Carilion Clinic /ID# 227832
    Roanoke, Virginia 24016, United States
  • Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich /ID# 222569
    Ciudad Autonoma Buenos Aires, Buenos Aires 1426, Argentina
  • Hospital Interzonal General de Agudos General Jose de San Martin /ID# 221893
    La Plata, Buenos Aires 1900, Argentina
  • CER Instituto Medico /ID# 223175
    Quilmes, Buenos Aires 1878, Argentina
  • Aprillus Asistencia e Investigacion /ID# 221890
    Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires 1958, Argentina
  • Instituto CAICI S.R.L /ID# 221892
    Rosario, Santa Fe 2000, Argentina
  • Centro de Investigaciones Medicas Tucuman /ID# 221888
    San Miguel de Tucuman, Tucuman 4000, Argentina
  • Investigaciones Clinicas Tucuman /ID# 221889
    San Miguel de Tucuman, Tucuman 4000, Argentina
  • Rheumatology Research Unit Sunshine Coast /ID# 221816
    Maroochydore, Queensland 4558, Australia
  • Emeritus Research /ID# 223027
    Camberwell, Victoria 3124, Australia
  • Monash Medical Centre /ID# 221814
    Clayton, Victoria 3168, Australia
  • UMHAT Sveti Ivan Rilski /ID# 223358
    Sofia, 1431, Bulgaria
  • UMHAT Sveti Ivan Rilski /ID# 223359
    Sofia, 1431, Bulgaria
  • Duplicate_Peking Union Medical College Hospital /ID# 222950
    Beijing, Beijing 100730, China
  • Guangdong Provincial People's Hospital /ID# 222851
    Guangzhou, Guangdong 510080, China
  • People's Hospital of Xinjiang /ID# 222928
    Urumqi, Guizhou 830001, China
  • Huashan Hospital, Fudan University /ID# 222929
    Shanghai, Shanghai 200040, China
  • Duplicate_Centro Integral de Reumatologia del Caribe Circaribe SAS /ID# 221879
    Barranquilla, Atlantico 80002, Colombia
  • Duplicate_Centro de Investigacion en Reumatologia y Especialidades Medicas- CIRE /ID# 221884
    Bogota, Cundinamarca 110221, Colombia
  • Preventive Care Sas /Id# 221881
    Chia, Cundinamarca 250001, Colombia
  • Healthy Medical Center S.A.S /ID# 221882
    Zipaquirá, Cundinamarca 250252, Colombia
  • Clinica Universitaria Bolivari /ID# 221880
    Medellin, Valle Del Cauca 050034, Colombia
  • Duplicate_Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 222963
    Berlin, 10117, Germany
  • Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 222964
    Dresden, 01307, Germany
  • Duplicate_Debreceni Egyetem Klinikai Kozpont /ID# 222480
    Debrecen, Hajdu-Bihar 4032, Hungary
  • Vital Medicina Kft /ID# 222479
    Veszprém, Veszprem 8200, Hungary
  • Duplicate_Azienda Ospedaliero-Universitaria di Ferrara-Arcispedale Sant Anna /ID# 221919
    Cona, Ferrara 44124, Italy
  • Chukyo Hospital /ID# 223398
    Nagoya-shi, Aichi 457-8510, Japan
  • NHO Nagoya Medical Center /ID# 222397
    Nagoya-shi, Aichi 460-0001, Japan
  • Hospital of the University of Occupational and Environmental Health, Japan /ID# 222499
    Kitakyushu-shi, Fukuoka 807-8556, Japan
  • Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital /ID# 222393
    Hiroshima-shi, Hiroshima 730-8619, Japan
  • National Hospital Organization Asahikawa Medical Center /ID# 222394
    Asahikawa-shi, Hokkaido 070-8644, Japan
  • EIRAKU Internal Medicine Clinic /ID# 222385
    Kagoshima-shi, Kagoshima 890-0063, Japan
  • Tohoku University Hospital /ID# 222392
    Sendai-shi, Miyagi 9808574, Japan
  • Shinshu University Hospital /ID# 222395
    Matsumoto-shi, Nagano 390-8621, Japan
  • Saitama Medical Center /ID# 222389
    Kawagoe-shi, Saitama 350-8550, Japan
  • Keio University Hospital /ID# 222498
    Shinjuku-ku, Tokyo 160-8582, Japan
  • Seoul National University Hospital /ID# 221897
    Seoul, Seoul Teugbyeolsi 03080, Korea, Republic of
  • RM Pharma Specialists S.A de C.V. /ID# 221915
    Mexico City, Ciudad De Mexico 03100, Mexico
  • CINTRE, Centro de Investigación y Tratamiento Reumatológico SC /ID# 221913
    Mexico City, Ciudad De Mexico 11850, Mexico
  • Morales Vargas Centro de Investigacion S.C. /ID# 221912
    Leon, Guanajuato 37000, Mexico
  • Centro Integral en Reumatologia S.A de C.V /ID# 221914
    Guadalajara, Jalisco 44160, Mexico
  • Centro de Estudios de Investigación Básica y Clínica, S.C. /ID# 221910
    Guadalajara, Jalisco 44690, Mexico
  • Medical Care & Research SA de CV /ID# 221911
    Mérida, Yucatan 97070, Mexico
  • North Shore Hospital /ID# 221850
    Takapuna, Auckland 0622, New Zealand
  • WroMedica I. Bielicka, A. Strzalkowska s.c. /ID# 221860
    Wroclaw, Dolnoslaskie 51-685, Poland
  • Centrum Nowoczesnych Terapii Dobry Lekarz Sp. z o.o. /ID# 224430
    Krakow, Malopolskie 31-011, Poland
  • MTZ Clinical Research Powered by Pratia /ID# 224431
    Warszawa, Mazowieckie 02-172, Poland
  • Ortopedyczno-Rehabilitacyjny Szpital Kliniczny im. Wiktora Degi /ID# 221859
    Poznan, Wielkopolskie 61-545, Poland
  • GCM Medical Group PSC /ID# 224394
    San Juan, 00917-3104, Puerto Rico
  • Mindful Medical Research /ID# 222513
    San Juan, 00918-3756, Puerto Rico
  • HUA - Txagorritxu /ID# 221992
    Vitoria, Alava 01009, Spain
  • Consorci Corporacio Sanitaria Parc Tauli Sabadell /ID# 221995
    Sabadell, Barcelona 08208, Spain
  • Hospital Universitario Basurto /ID# 221999
    Bilbao, Vizcaya 48013, Spain
  • Hospital Universitario de Galdakao /ID# 221996
    Galdakao, Vizcaya 48960, Spain
  • Duplicate_Hospital Universitario A Coruna - CHUAC /ID# 221993
    A Coruna, 15006, Spain
  • Hospital Universitario 12 de Octubre /ID# 221994
    Madrid, 28041, Spain
  • Hospital Universitario Virgen de Valme /ID# 221997
    Sevilla, 41014, Spain
  • Hospital Universitario y Politecnico La Fe /ID# 221998
    Valencia, 46026, Spain
  • Taichung Veterans General Hospital /ID# 221748
    Taichung, Keelung 40705, Taiwan
  • Taipei Veterans General Hosp /ID# 221746
    Taipei, Keelung 11217, Taiwan
  • National Taiwan University Hospital /ID# 221745
    Taipei City, Taipei 100, Taiwan
  • China Medical University Hospital /ID# 221747
    Taichung, 40447, Taiwan
  • Taipei Medical University Hospital /ID# 227653
    Taipei City, 11031, Taiwan
  • Linkou Chang Gung Memorial Hospital /ID# 222469
    Taoyuan City, 333, Taiwan
  • Guys and St Thomas NHS Foundation Trust /ID# 221863
    London, London, City Of SE1 9RT, United Kingdom
  • Duplicate_Manchester University NHS Foundation Trust /ID# 221861
    Manchester, M13 9WL, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Jan 2024, 41 months.

Results were first posted in Jan 2025, 1 year after primary completion.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 41 months is above that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2020
First posted
Jun 30, 2020
StartActual
Jul 27, 2020
Primary completionActual
Jan 3, 2024
CompletionActual
Jan 3, 2024
Results first posted
Jan 14, 2025
Last update
Jan 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04451772
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Jul 27, 2020
Primary completion
Jan 3, 2024
Completion
Jan 3, 2024
Results posted
Jan 14, 2025
Last update
Jan 14, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elsubrutinib · Upadacitinib

Start the discussion